Back
EHRA Premium Access

Non-invasive continuous arterial pressure monitoring during transcatheter atrial fibrillation ablation: a feasibility prospective study

Session: Moderated ePosters - Update on new techonologies and strategies to improve outcome of atrial fibrillation ablation
Topic: Rhythm Control, Catheter Ablation
Speaker: Doctor M. Parollo (Pisa, IT)
Event: EHRA 2022

Congress Presentation

About the speaker

Doctor Matteo Parollo

Azienda Ospedaliero Universitaria Pisana, Pisa (Italy)
2 presentations
0 follower

6 more presentations in this session

First real-world experience with pulmonary vein isolation using pulsed field ablation for paroxysmal atrial fibrillation

Speaker: Associate Professor K. Neven (Essen, DE)

Access
Abstract
Slides
Thumbnail

Feasibility of a novel algorithm for automated reconstruction of the left atrial anatomy based on intracardiac echocardiography

Speaker: Doctor F. Akerstrom (Stockholm, SE)

Access
Abstract
Slides
Thumbnail

Left atrial anatomical variations correlate with atrial fibrillation sources near the left atrial ridge

Speaker: Doctor R. Gagyi (Rotterdam, NL)

Access
Abstract
Slides
Thumbnail

Long term outcome after ablation of persistent atrial fibrillation in patients with postprocedurally unmasked sinus node disease

Speaker: Mrs E. Martini (Munich, DE)

Access
Abstract
Slides
Thumbnail

Modern technologies for radiofrequency pulmonary vein isolation. Comparison of radiofrequency balloon catheter with high power-short duration ablation in patients with paroxysmal atrial fibrillation

Speaker: Doctor J. van den Bruck (Cologne, DE)

Access
Abstract
Slides
Thumbnail

Access the full session

Moderated ePosters - Update on new techonologies and strategies to improve outcome of atrial fibrillation ablation

Speakers: Doctor M. Parollo, Associate Professor K. Neven, Doctor F. Akerstrom, Doctor R. Gagyi, Mrs E. Martini...
Access
Thumbnail

About the event

Image

EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb